IL277577A - Antibody-based methods for the detection and treatment of Alzheimer's disease - Google Patents

Antibody-based methods for the detection and treatment of Alzheimer's disease

Info

Publication number
IL277577A
IL277577A IL277577A IL27757720A IL277577A IL 277577 A IL277577 A IL 277577A IL 277577 A IL277577 A IL 277577A IL 27757720 A IL27757720 A IL 27757720A IL 277577 A IL277577 A IL 277577A
Authority
IL
Israel
Prior art keywords
antibody
disease
detecting
based methods
treating alzheimer
Prior art date
Application number
IL277577A
Other languages
English (en)
Hebrew (he)
Original Assignee
Axon Neuroscience Se
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Axon Neuroscience Se filed Critical Axon Neuroscience Se
Publication of IL277577A publication Critical patent/IL277577A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL277577A 2018-03-28 2020-09-24 Antibody-based methods for the detection and treatment of Alzheimer's disease IL277577A (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201862649208P 2018-03-28 2018-03-28
US201862664662P 2018-04-30 2018-04-30
US201862703299P 2018-07-25 2018-07-25
PCT/IB2019/000358 WO2019186276A2 (en) 2018-03-28 2019-03-27 Antibody-based methods of detecting and treating alzheimer's disease

Publications (1)

Publication Number Publication Date
IL277577A true IL277577A (en) 2020-11-30

Family

ID=66999856

Family Applications (1)

Application Number Title Priority Date Filing Date
IL277577A IL277577A (en) 2018-03-28 2020-09-24 Antibody-based methods for the detection and treatment of Alzheimer's disease

Country Status (12)

Country Link
EP (1) EP3774887A2 (ru)
JP (1) JP2021520777A (ru)
KR (1) KR20200144551A (ru)
CN (1) CN112236452A (ru)
AU (1) AU2019244481A1 (ru)
BR (1) BR112020018868A2 (ru)
CA (1) CA3095443A1 (ru)
IL (1) IL277577A (ru)
MX (1) MX2020009991A (ru)
RU (1) RU2020135052A (ru)
SG (1) SG11202008098TA (ru)
WO (1) WO2019186276A2 (ru)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201506244VA (en) 2013-03-13 2015-09-29 Prothena Biosciences Ltd Tau immunotherapy
DK3452507T3 (da) 2016-05-02 2022-11-14 Prothena Biosciences Ltd Tau-immunoterapi
BR112018072389A2 (pt) 2016-05-02 2019-02-19 Prothena Biosciences Limited anticorpos que reconhecem tau
SG11201910066QA (en) 2017-05-02 2019-11-28 Prothena Biosciences Ltd Antibodies recognizing tau
TW202100550A (zh) 2019-03-03 2021-01-01 愛爾蘭商普羅帝納生物科學公司 識別ｔａｕ之抗體
CA3150156A1 (en) 2019-09-09 2021-03-18 Michal Novak BIOMARKERS AND TREATMENTS FOR ALZHEIMER'S DISEASE AND MILD COGNITIVE DISORDER
EP4263599A1 (en) * 2020-12-16 2023-10-25 Voyager Therapeutics, Inc. Tau binding compounds
BR112023014151A2 (pt) * 2021-02-19 2023-10-10 Eisai R&D Man Co Ltd Anticorpo tau anti-pt217
CN117003863A (zh) * 2022-04-28 2023-11-07 厦门大学 针对p-tau 217的抗体及其用途
CN114778856B (zh) * 2022-05-30 2023-03-17 苏州宇测生物科技有限公司 磷酸化tau蛋白检测试剂盒
WO2024040212A2 (en) * 2022-08-19 2024-02-22 Staidson Biopharma Inc. Antibodies specifically recognizing programmed cell death 1 ligand 1 and uses thereof
CN117624351B (zh) * 2023-11-24 2024-07-05 无锡傲锐东源生物科技有限公司 一种抗人磷酸化tau181兔单克隆抗体及其应用

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4880935A (en) 1986-07-11 1989-11-14 Icrf (Patents) Limited Heterobifunctional linking agents derived from N-succinimido-dithio-alpha methyl-methylene-benzoates
WO1988007089A1 (en) 1987-03-18 1988-09-22 Medical Research Council Altered antibodies
US5204244A (en) 1987-10-27 1993-04-20 Oncogen Production of chimeric antibodies by homologous recombination
US5202238A (en) 1987-10-27 1993-04-13 Oncogen Production of chimeric antibodies by homologous recombination
IL106992A (en) 1988-02-11 1994-06-24 Bristol Myers Squibb Co Noble hydrazonic history of anthracycline and methods for their preparation
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
US5112596A (en) 1990-04-23 1992-05-12 Alkermes, Inc. Method for increasing blood-brain barrier permeability by administering a bradykinin agonist of blood-brain barrier permeability
US5268164A (en) 1990-04-23 1993-12-07 Alkermes, Inc. Increasing blood-brain barrier permeability with permeabilizer peptides
US6797492B2 (en) 1991-05-17 2004-09-28 Merck & Co., Inc. Method for reducing the immunogenicity of antibody variable domains
US5262522A (en) 1991-11-22 1993-11-16 Immunex Corporation Receptor for oncostatin M and leukemia inhibitory factor
US5622929A (en) 1992-01-23 1997-04-22 Bristol-Myers Squibb Company Thioether conjugates
EP0652775B1 (en) 1992-07-27 2000-04-19 THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by the SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES Targeting of liposomes to the blood-brain barrier
US6214345B1 (en) 1993-05-14 2001-04-10 Bristol-Myers Squibb Co. Lysosomal enzyme-cleavable antitumor drug conjugates
US5457035A (en) 1993-07-23 1995-10-10 Immunex Corporation Cytokine which is a ligand for OX40
CU22615A1 (es) 1994-06-30 2000-02-10 Centro Inmunologia Molecular Procedimiento de obtención de anticuerpos monoclonales murinos menos inmunogénicos. anticuerpos monoclonales obtenidos
PT1516628E (pt) 1995-07-27 2013-09-24 Genentech Inc Formulação de proteína liofilizada isotónica estável
WO1997023243A1 (en) 1995-12-22 1997-07-03 Bristol-Myers Squibb Company Branched hydrazone linkers
WO1998022120A1 (en) * 1996-11-19 1998-05-28 The Wistar Institute Of Anatomy & Biology Diagnostic and therapeutic reagents for alzheimer's disease
JP2002512624A (ja) 1997-05-21 2002-04-23 バイオベーション リミテッド 非免疫原性タンパク質の製造方法
US6514221B2 (en) 2000-07-27 2003-02-04 Brigham And Women's Hospital, Inc. Blood-brain barrier opening
US20030083299A1 (en) 2000-11-04 2003-05-01 Ferguson Ian A. Non-invasive delivery of polypeptides through the blood-brain barrier
DE10121982B4 (de) 2001-05-05 2008-01-24 Lts Lohmann Therapie-Systeme Ag Nanopartikel aus Protein mit gekoppeltem Apolipoprotein E zur Überwindung der Blut-Hirn-Schranke und Verfahren zu ihrer Herstellung
AU2003246664B2 (en) 2002-07-12 2007-06-14 Axon Neuroscience Se Transgenic animal expressing Alzheimer's tau protein
KR101111477B1 (ko) 2002-12-03 2012-02-23 블랜체트 록펠러 뉴로사이언시즈 인스티튜트 치료제와 연결된 콜레스테롤을 포함하는 접합체
MXPA05006940A (es) 2002-12-24 2006-02-22 Neurochem Int Ltd Formulaciones terapeuticas para el tratamiento de enfermedades relacionadas con beta - amiloide.
SI1725249T1 (sl) 2003-11-06 2014-04-30 Seattle Genetics, Inc. Spojine monometilvalina, sposobne konjugacije na ligande
WO2006034488A2 (en) 2004-09-23 2006-03-30 Genentech, Inc. Cysteine engineered antibodies and conjugates
US8012936B2 (en) 2006-03-29 2011-09-06 New York University Tau fragments for immunotherapy
WO2008140639A2 (en) * 2007-02-08 2008-11-20 Oligomerix, Inc. Biomarkers and assays for alzheimer's disease
US8093018B2 (en) * 2008-05-20 2012-01-10 Otsuka Pharmaceutical Co., Ltd. Antibody identifying an antigen-bound antibody and an antigen-unbound antibody, and method for preparing the same
US8613924B2 (en) * 2009-08-06 2013-12-24 Immunas Pharma, Inc. Antibodies that specifically bind to A beta oligomers and use thereof
CN109265543B (zh) 2011-09-19 2022-04-26 阿克松神经系统科学公司 阿尔茨海默病中的tau蛋白介导病变的基于蛋白质的疗法和诊断
SI2794654T1 (sl) * 2011-12-20 2019-08-30 Janssen Biotech, Inc. Protitelesa proti PHF-tau njihove uporabe
US8853505B2 (en) * 2012-02-27 2014-10-07 Syngenta Participations Ag Variety corn line AA2205
US8980270B2 (en) * 2013-01-18 2015-03-17 Ipierian, Inc. Methods of treating a tauopathy
RU2730668C2 (ru) 2014-11-19 2020-08-24 Аксон Ньюросайенс Се Гуманизированные тау-антитела при болезни альцгеймера
CN107531797B (zh) * 2016-02-05 2021-07-02 江苏恒瑞医药股份有限公司 凝血酶抗体、其抗原结合片段及医药用途

Also Published As

Publication number Publication date
EP3774887A2 (en) 2021-02-17
AU2019244481A1 (en) 2020-10-01
KR20200144551A (ko) 2020-12-29
SG11202008098TA (en) 2020-10-29
CA3095443A1 (en) 2019-10-03
WO2019186276A2 (en) 2019-10-03
JP2021520777A (ja) 2021-08-26
RU2020135052A (ru) 2022-04-29
WO2019186276A8 (en) 2020-10-15
BR112020018868A2 (pt) 2021-01-26
CN112236452A (zh) 2021-01-15
MX2020009991A (es) 2020-10-14
WO2019186276A3 (en) 2020-02-27

Similar Documents

Publication Publication Date Title
IL277577A (en) Antibody-based methods for the detection and treatment of Alzheimer's disease
IL254030B (en) Use of pyridofidine to improve cognitive function and to treat Alzheimer's disease
IL280315A (en) Methods for treating and preventing Alzheimer's disease
IL263433A (en) Methods for treating Alzheimer's disease
ZA201605341B (en) Methods of treating alzheimer's disease
SG11201606490YA (en) Methods of treating alzheimer's disease
SG11202011296VA (en) Compositions and methods for the treatment of parkinson's disease
EP3458036A4 (en) METHODS OF TREATING OR PREVENTING ALZHEIMER'S DISEASE AND RELATED CONDITIONS
EP3377118A4 (en) METHOD FOR THE TREATMENT OF MORBUS ALZHEIMER AND RELATED DISEASES
IL288894A (en) Methods for the assessment and treatment of Alzheimer's disease and their applications
IL276896A (en) Methods for treating Crohn's disease with a specific anti-IL23 antibody
EP3558340A4 (en) METHOD FOR USE OF GM6 IN DIAGNOSIS AND TREATMENT OF MORBUS ALZHEIMER
MA45865A (fr) Procédés de détection et de traitement d'une tumeur exprimant pt346 pdk1
IL277182A (en) Compositions and methods for treating parkinson's disease
EP3347486A4 (en) REDUCTION OF ER-MAM-LOCALIZED APP-C99 AND METHOD FOR THE TREATMENT OF ALZHEIMER DISEASE
IL281395A (en) Treatment of early stages of Alzheimer's by replacing a small volume of plasma
ZA202101489B (en) Compositions and methods for the treatment of parkinson's disease
EP3490546A4 (en) METHOD FOR TREATING OR PREVENTING AMYLOID-related IMAGING ANOMALIES IN CONNECTION WITH THE TREATMENT OF MORBUS ALZHEIMER
IL248935A0 (en) Diagnostic testing and treatment/prevention of Alzheimer's disease
PL3137097T3 (pl) Leczenie i profilaktyka choroby Alzheimera (AD)
EP3773500A4 (en) COMPOSITIONS AND METHODS FOR DETECTION AND TREATMENT OF ALZHEIMER'S DISEASE
HUE037501T2 (hu) Alzheimer-kór (AD) kezelése és megelõzése
DK3137094T3 (da) Behandling og forebyggelse af alzheimers sygdom (ad)
SG11202101274XA (en) Benzimidazole compounds and use thereof for treating alzheimer's disease or huntington's disease
IL265656A (en) Preparations and methods for the treatment of Alzheimer's disease and Parkinson's disease